{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:43:35Z","timestamp":1770284615885,"version":"3.49.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":39,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver Transpl"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:p>A national, multicenter, retrospective study was conducted to assess the results obtained for liver transplant recipients with conversion to everolimus in daily practice. The study included 477 recipients (481 transplantations). Indications for conversion to everolimus were renal dysfunction (32.6% of cases), hepatocellular carcinoma (HCC; 30.2%; prophylactic treatment for 68.9%), and de novo malignancy (29.7%). The median time from transplantation to conversion to everolimus was 68.7 months for de novo malignancy, 23.8 months for renal dysfunction, and 7.1 months for HCC and other indications. During the first year of treatment, mean everolimus trough levels were 5.4 (standard deviation [SD], 2.7) ng\/mL and doses remained stable (1.5 mg\/day) from the first month after conversion. An everolimus monotherapy regimen was followed by 28.5% of patients at 12 months. Patients with renal dysfunction showed a glomerular filtration rate (4\u2010variable Modification of Diet in Renal Disease) increase of 10.9 mL (baseline mean, 45.8 [SD, 25.3] versus 57.6 [SD, 27.6] mL\/minute\/1.73 m<jats:sup>2<\/jats:sup>) at 3 months after everolimus initiation (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), and 6.8 mL at 12 months. Improvement in renal function was higher in patients with early conversion (&lt;1 year). Adverse events were the primary reason for discontinuation in 11.2% of cases. The probability of survival at 3 years after conversion to everolimus was 83.0%, 71.1%, and 59.5% for the renal dysfunction, de novo malignancy, and HCC groups, respectively. Everolimus is a viable option for the treatment of renal dysfunction, and earlier conversion is associated with better recovery of renal function. Prospective studies are needed to confirm advantages in patients with malignancy. <jats:italic toggle=\"yes\">Liver Transpl 21:1056\u20101065, 2015<\/jats:italic>. \u00a9 2015 AASLD.<\/jats:p>","DOI":"10.1002\/lt.24172","type":"journal-article","created":{"date-parts":[[2015,5,19]],"date-time":"2015-05-19T23:53:03Z","timestamp":1432079583000},"page":"1056-1065","source":"Crossref","is-referenced-by-count":36,"title":["Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain"],"prefix":"10.1097","volume":"21","author":[{"given":"Itxarone","family":"Bilbao","sequence":"first","affiliation":[{"name":"Unidad de Trasplante Hep\u00e1tico, Hospital Universitario Vall d'Hebron, Network Center for Biomedical Research in Hepatic and Digestive Diseases (CIBERehd),Universidad Aut\u00f3noma Barcelona,Barcelona,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Salcedo","sequence":"additional","affiliation":[{"name":"Hospital Gregorio Mara\u00f1\u00f3n,CIBERehd,Madrid,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Angel","family":"G\u00f3mez","sequence":"additional","affiliation":[{"name":"Hospital Virgen del Rocio,Sevilla,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Hospital Doce de Octubre,Madrid,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Castroagud\u00edn","sequence":"additional","affiliation":[{"name":"Hospital Universitario,Santiago de Compostela,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Fabregat","sequence":"additional","affiliation":[{"name":"Hospital de Bellvitge,Barcelona,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Almohalla","sequence":"additional","affiliation":[{"name":"Hospital del Rio Hortega,Valladolid,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Herrero","sequence":"additional","affiliation":[{"name":"Clinica Universidad de Navarra,CIBERehd,Navarra,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valent\u00edn","family":"Cuervas\u2010Mons","sequence":"additional","affiliation":[{"name":"Hospital Puerta de Hierro,Madrid,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra","family":"Otero","sequence":"additional","affiliation":[{"name":"Hospital Universitario,A Coru\u00f1a,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel","family":"Rub\u00edn","sequence":"additional","affiliation":[{"name":"Hospital La Fe,CIBERehd,Valencia,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Miras","sequence":"additional","affiliation":[{"name":"Hospital Virgen de la Arrixaca,Murcia,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Rodrigo","sequence":"additional","affiliation":[{"name":"Hospital Carlos Haya,M\u00e1laga,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trinidad","family":"Serrano","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Lozano Blesa,Zaragoza,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Crespo","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic Barcelona,CIBERehd,Barcelona,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel De la","family":"Mata","sequence":"additional","affiliation":[{"name":"Hospital Reina Sof\u00eda, CIBERehd,C\u00f3rdoba,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Bustamante","sequence":"additional","affiliation":[{"name":"Hospital de Cruces,Bilbao,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Luisa","family":"Gonzalez\u2010Dieguez","sequence":"additional","affiliation":[{"name":"Hospital Central de Asturias,Oviedo,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Moreno","sequence":"additional","affiliation":[{"name":"Hospital Nuestra Se\u00f1ora de la Candelaria,Tenerife,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isidoro","family":"Narvaez","sequence":"additional","affiliation":[{"name":"Hospital Infanta Cristina,Badajoz,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magda","family":"Guilera","sequence":"additional","affiliation":[{"name":"Novartis Farmac\u00e9utica,Barcelona,Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the EVEROLIVER study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2015,7,24]]},"reference":[{"key":"lt24172-bib-0001-20240115","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4065\/78.2.197","article-title":"Recent advances in liver transplantation","volume":"78","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"lt24172-bib-0002-20240115","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1097\/00007890-200112270-00012","article-title":"End\u2010stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin\u2010based immunotherapy: risk of development and treatment","volume":"72","year":"2001","journal-title":"Transplantation"},{"key":"lt24172-bib-0003-20240115","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1177\/039139881003301105","article-title":"Chronic kidney disease after liver transplantation: Recent evidence","volume":"33","year":"2010","journal-title":"Int J Artif Organs"},{"issue":"suppl 2","key":"lt24172-bib-0004-20240115","first-page":"S70","article-title":"Outcomes after liver transplantation: chronic kidney disease","volume":"15","year":"2009","journal-title":"Liver Transpl"},{"key":"lt24172-bib-0005-20240115","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.jhep.2011.06.015","article-title":"m\u2010TOR inhibitors: what role in liver transplantation?","volume":"55","year":"2011","journal-title":"J Hepatol"},{"key":"lt24172-bib-0006-20240115","first-page":"153","article-title":"Immunosuppression in liver transplantation: moving forward to the ideal regimen","volume":"15","year":"2012","journal-title":"Organs, Tissues Cells"},{"key":"lt24172-bib-0007-20240115","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial","volume":"12","year":"2012","journal-title":"Am J Transplant"},{"key":"lt24172-bib-0008-20240115","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/ajt.12280","article-title":"Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study","volume":"13","year":"2013","journal-title":"Am J Transplant"},{"key":"lt24172-bib-0009-20240115","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1432-2277.2008.00768.x","article-title":"Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function","volume":"22","year":"2009","journal-title":"Transpl Int"},{"key":"lt24172-bib-0010-20240115","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/lt.21920","article-title":"Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction","volume":"15","year":"2009","journal-title":"Liver Transpl"},{"key":"lt24172-bib-0011-20240115","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/lt.22292","article-title":"Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis","volume":"17","year":"2011","journal-title":"Liver Transpl"},{"key":"lt24172-bib-0012-20240115","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/lt.21827","article-title":"Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial","volume":"15","year":"2009","journal-title":"Liver Transpl"},{"key":"lt24172-bib-0013-20240115","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1111\/j.1600-6143.2010.03128.x","article-title":"Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function","volume":"10","year":"2010","journal-title":"Am J Transplant"},{"key":"lt24172-bib-0014-20240115","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/lt.21420","article-title":"Sirolimus\u2010based immunosuppression following liver transplantation for hepatocellular carcinoma","volume":"14","year":"2008","journal-title":"Liver Transpl"},{"key":"lt24172-bib-0015-20240115","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hep.23437","article-title":"Sirolimus\u2010based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma","volume":"51","year":"2010","journal-title":"Hepatology"},{"key":"lt24172-bib-0016-20240115","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.transproceed.2012.07.079","article-title":"Antitumor efficacy of mammalian target of rapamycin inhibitor therapy in liver transplant recipients with oncological disease: a case\u2010control study","volume":"44","year":"2012","journal-title":"Transplant Proc"},{"key":"lt24172-bib-0017-20240115","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5500\/wjt.v4.i2.133","article-title":"Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients","volume":"4","year":"2014","journal-title":"World J Transplant"},{"key":"lt24172-bib-0018-20240115","first-page":"845438","article-title":"The role of mTOR inhibitors in liver transplantation: reviewing the evidence","volume":"2014","year":"2014","journal-title":"J Transplant"},{"key":"lt24172-bib-0019-20240115","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1111\/j.1600-6143.2011.03767.x","article-title":"Limiting hepatitis C virus progression in liver transplant recipients using sirolimus\u2010based immunosuppression","volume":"11","year":"2011","journal-title":"Am J Transplant"},{"key":"lt24172-bib-0020-20240115","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jhep.2010.10.044","article-title":"Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis","volume":"55","year":"2011","journal-title":"J Hepatol"},{"key":"lt24172-bib-0021-20240115","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.transproceed.2009.06.087","article-title":"Indications and management of everolimus after liver transplantation","volume":"41","year":"2009","journal-title":"Transplant Proc"},{"key":"lt24172-bib-0022-20240115","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.transproceed.2010.02.014","article-title":"Management of hepatocellular carcinoma recurrence after liver transplantation","volume":"42","year":"2010","journal-title":"Transplant Proc"},{"key":"lt24172-bib-0023-20240115","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.tp.0000280549.93403.dd","article-title":"Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms","volume":"84","year":"2007","journal-title":"Transplantation"},{"key":"lt24172-bib-0024-20240115","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.transproceed.2013.01.075","article-title":"Everolimus monotherapy or combined therapy in liver transplantation: indications and results","volume":"45","year":"2013","journal-title":"Transplant Proc"},{"key":"lt24172-bib-0025-20240115","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.transproceed.2009.06.083","article-title":"Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation","volume":"41","year":"2009","journal-title":"Transplant Proc"},{"key":"lt24172-bib-0026-20240115","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate Glomerular filtration rate","volume":"150","year":"2009","journal-title":"Ann Intern Med"},{"key":"lt24172-bib-0027-20240115","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","year":"2003","journal-title":"N Engl J Med"},{"key":"lt24172-bib-0028-20240115","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5500\/wjt.v5.i1.26","article-title":"Underestimation of chronic renal dysfunction after liver transplantation in daily practice: ICEBERG study","volume":"5","year":"2015","journal-title":"World J Transplant"},{"key":"lt24172-bib-0029-20240115","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1016\/j.transproceed.2006.10.054","article-title":"Renal disease burden following liver transplantation","volume":"38","year":"2006","journal-title":"Transplant Proc"},{"key":"lt24172-bib-0030-20240115","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced\u2010exposure CsA versus mycophenolic acid plus standard\u2010exposure CsA in renal\u2010transplant recipients","volume":"10","year":"2010","journal-title":"Am J Transplant"},{"key":"lt24172-bib-0031-20240115","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1432-2277.2012.01465.x","article-title":"Everolimus plus early tacrolimus minimization: a phase III, randomized, open\u2010label, multicentre trial in renal transplantation","volume":"25","year":"2012","journal-title":"Transpl Int"},{"key":"lt24172-bib-0032-20240115","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/ajt.12615","article-title":"Everolimus and early calcineurin inhibitor withdrawal: 3\u2010year results from a randomized trial in liver transplantation","volume":"14","year":"2014","journal-title":"Am J Transplant"},{"key":"lt24172-bib-0033-20240115","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1600-6143.2012.04049.x","article-title":"A randomized, controlled study to assess the conversion from calcineurin inhibitors to everolimus after liver transplantation\u2010\u2010PROTECT","volume":"12","year":"2012","journal-title":"Am J Transplant"},{"key":"lt24172-bib-0034-20240115","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/tri.12372","article-title":"Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review","volume":"27","year":"2014","journal-title":"Transpl Int"},{"key":"lt24172-bib-0035-20240115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5500\/wjt.v4.i2.122","article-title":"Multiple indications for everolimus after liver transplantation in current clinical practice","volume":"4","year":"2014","journal-title":"World J Transplant"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.24172","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201508000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T03:00:21Z","timestamp":1705287621000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201508000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,24]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.24172","relation":{},"ISSN":["1527-6465","1527-6473"],"issn-type":[{"value":"1527-6465","type":"print"},{"value":"1527-6473","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,24]]}}}